RxDoctor Payments Data

Rachael Schuman, NP

Adult Health · Freeport, NYNPI 1366851982

Payments from drug & device makers

$1,222in general payments, 2019–2025

Across 21 payments — averaging $58.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$444
  • Boston Scientific$273
  • AstraZeneca$167
  • Boehringer Ingelheim$119
  • Scpharmaceuticals Inc.$50
  • Merck$36
  • plus $134 from 6 others

What the payments were for

  • Food & beverage$1,222100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,222 in reported general payments places this provider in the 70th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$38,478
Medicare patients
285
Services billed
474

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban71$90,556
XareltoRivaroxaban38$41,637
EntrestoSacubitril/Valsartan20$32,402
JardianceEmpagliflozin12$19,520
Praluent PenAlirocumab15$18,469
FarxigaDapagliflozin Propanediol11$16,242
BrilintaTicagrelor11$12,534
Nebivolol Hcl16$2,052
Ezetimibe71$1,528
Atorvastatin Calcium116$1,123
Metoprolol Succinate66$1,093
Rosuvastatin Calcium42$548
Nifedipine ErNifedipine11$489
ClopidogrelClopidogrel Bisulfate44$422
Amlodipine Besylate38$352

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$24$90,55671 claims
AstraZenecaFarxiga, Brilinta$167$28,77522 claims
Boehringer IngelheimJardiance$119$19,52012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,828 adult health providers in New York.

Other adult health in Freeport

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →